Last edition
News about
Novo Nordisk Introduces Wegovy Pill with knownwell as NovoCare Provider
Novo Nordisk has launched Wegovy in an oral pill form, marking the first FDA-approved oral GLP-1 therapy, with knownwell recognised as a NovoCare provider to support broader patient access to clinician-led metabolic care across the US.
FUJIFILM Irvine Scientific Rebrands as FUJIFILM Biosciences
FUJIFILM Irvine Scientific has officially rebranded as FUJIFILM Biosciences, formalising the Life Sciences Group restructuring announced in June and reflecting its expanded life sciences portfolio built on over 55 years of cell culture expertise.
US FDA Advances Review of Tzield in Young Children
The FDA has accepted Sanofi’s sBLA for Tzield under priority review, seeking broader pediatric use in delaying type 1 diabetes onset.
China Approves Nucala from GSK for Adult COPD Treatment
China has approved Nucala (mepolizumab) for adult COPD, supported by phase-III MATINEE and METREX trials showing reduced exacerbations in patients with blood eosinophil counts from 150 cells/µL.
China Approves Azstarys for ADHD Treatment
ArkBio secures NMPA nod for once-daily ADHD treatment in China.
Insilico Medicine and Servier Forge AI-Driven Oncology Drug Discovery Alliance
Insilico Medicine, a global leader in artificial intelligence–driven drug discovery, has entered into a multi-year research and development collaboration with Servier, an independent international pharmaceutical company governed by a foundation.
Semaglutide Patent Expiry to Open Over USD 600 Million Opportunity for Generic Drugmakers
Industry estimates suggest that around 10 to 15 domestic and global drugmakers are likely to compete for this opportunity. In India, the introduction of generic semaglutide formulations, expected during the 2026–27 financial year, could generate incremental revenues of approximately USD 12–24 million within the branded formulations market.
Generic Drug Maker Hindustan Laboratories Files IPO Papers With SEBI
Hindustan Laboratories, an Indian manufacturer of generic pharmaceutical formulations, has filed draft papers with the Securities and Exchange Board of India (SEBI) to launch an initial public offering (IPO).
Torrent Pharma Approves USD 1.51 Billion Bond Fundraising Plan
Torrent Pharmaceuticals has approved a plan to raise up to USD 1.51 billion through the issuance of secured, rated, listed and redeemable non-convertible debentures (NCDs), according to a regulatory filing.
Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study
Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy